

Diseases of the Pancreas Jack Bragg DO, MACOI


I have no disclosures

I work for the Curators of the University of Missouri











Etiologies



- Autoimmune
- Drug-induced
- latrogenic
- IBD-related
- Infectious
- Inherited
- Metabolic
- Neoplastic
- Structural
- Toxic
- Traumatic
- Vascular







Sphincter of Oddi Dysfunction

Modified Biliary Classification

A = Elevated liver tests on 1 or more occasions **B** = Dilated Common Bile Duct **Biliary Type I – A+B Biliary Type II – A or B** Biliary Type III – Pain only




Drug Induced Pancreatitis Sorted by Incidence


Common asparaginase azathioprine 6-mercaptopurine didanosine (DDI) pentamidine valproate

Uncommon **ACE** inhibitors acetaminophen **5-amino ASA** furosemide sulfasalazine thiazides

Rare carbamazepine corticosteroids estrogens minocycline nitrofurantoin tetracycline








Local Effects of Enzymes

Inflammation
Third space losses
Fat necrosis
Pancreatic and peripancreatic necrosis

Danger Signals: First Few Hours



- Encephalopathy
- Hypoxemia
- Tachycardia >130/min
- Hypotension <90 mmHg</p>
- Hct >50
- Oliguria <50 ml/hr</p>
- Azotemia






Figure 1.

(A) Periumbilical ecchymosis (Cullen sign) and(B) flank ecchymosis (Grey Turner sign). Publishedwith permission from Chung and Chuang.¹



Grey-Turner Sign



Ranson's Criteria of Severity


At admission

- Age >55 years
- WBC >16,000/mm³
- Glucose >200 mg/dl
- LDH >350 IU/L
- AST >250 U/L

During initial 48 hours

- Hct decrease of >10
- BUN increase of >5 mg/dl
- Ca** <8 mg/dl</p>
- PaO₂ <60 mm Hg</p>
- Base deficit >4 mEq/L
- Fluid sequestration >6 L





Treatment


Supportive care

- Aggressive fluid and electrolyte replacement
- Monitoring Vital signs
 Urine output
 O₂ saturation
 Pain
- Analgesia, anti-emetics

Other treatments

- Acid suppression
- Antibiotics
- NG tube
- Nutritional support
- Urgent ERCP





Nutritional Support

 Consider when protracted course is likely

 Enteral vs parenteral Safety
 ? Effect on outcome

 Monitor calcium and triglycerides





Major Complications

Local

- Fluid collections
- Necrosis
- Infection
- Ascites
- Erosion into adjacent structures
- GI obstruction
- Hemorrhage

Systemic

- Pulmonary
- Renal
- CNS
- Multiorgan failure

Metabolic

- Hypocalcemia
- Hyperglycemia




Causes of mortality DEATH

Late (> one week)

- Multiorgan failure
- Pancreatic infections/sepsis

Early (< one week)


- Systemic inflammatory response syndrome (SIRS)
- Multiorgan failure




Reduction of Inflammation: Proposed Methods

 Remove impacted gallstones (papillotomy) Remove ascites (peritoneal lavage) Remove circulating proteases protease inhibitors fresh frozen plasma plasmapheresis stimulation of monocyte-macrophage system Remove O₂-derived free radicals

Progression to Pseudocyst






PSEUDOCYST


Complications

Severe pain Obstruction (CBD, duodenum) Dissection Bleeding Infection Leakage (ascites, pleural effusion) Rupture



Acute Pancreatitis: Necrosis

Progression










Pancreatic Necrosis




Non-perfusion

Systemic complications

 Local complications Hemorrhage Infection



Pancreatic Necrosis



Debridement

vs Observation



Signs of Infected Pancreatic Necrosis


 Increasing markers of inflammation (serum CRP, white blood cell count)

 Newly developed fever without extra pancreatic infection


 Signs of infection on CT (gas collection within areas of necrosis)




Necrosis











Pancreatic Necrosis

Treatment Strategies


Sterile

Medical therapy


 Debridement for persistent organ failure? Infected

Antibiotics

Debridement










Chronic Pancreatitis

Pain
Calcification
Pancreatic insufficiency


CHRONIC PANCREATITIS



Diabetes

Loss of insulin and glucagon


- Only in severe disease
- Brittle
- Insulin requirement low
- Ketoacidosis rare



Clinical Assessment

| Presentation | Order of evaluation |
|---------------|---|
| Pain | Imaging |
| Malabsorption | Imaging Trial of pancreatic enzymes Tests of pancreatic insufficiency |





CHRONIC PANCREATITIS











Splenic Vein Thrombosis



- Associated with chronic disease
- Splenomegaly
- Large gastric varices without esophageal varices
- Splenectomy for bleeding



Cystic Neoplasm



Clinical clues

- No prior pancreatitis
- Unexplained pancreatitis
- Cyst present on 1st CT

Diagnosis

- Fluid analysis
- EUS, ERCP
- Resection



Cystic Pancreatic Lesions

| Туре | Features | Cancer risk |
|--------------------------------|---|----------------|
| Pseudocyst | Macrocystic Thick wall | None |
| Serous cystadenoma | Micro- or macrocystic | Low |
| Mucinous cystadenoma | Macrocystic | High |
| Mucinous cystadenocarcinoma | Macrocystic Thick wall Intracystic mass | Cancer present |






Nutritional Management of Exocrine Insufficiency

Diet and exogenous enzymes Modify fat intake Medium chain triglycerides Enzyme replacement

- Coated vs uncoated
- Acid suppression





Vitamins, supplements Fat soluble Calcium Cyanocobalamin (B₁₂)



Pain Management

| Treatment | Effectiveness | |
|---------------------|---------------------|--|
| No alcohol | Low to moderate | |
| Analgesia | Moderate | |
| Enzyme replacement | Low | |
| Neurolytic therapy | Moderate short term | |
| Pseudocyst drainage | High | |
| Duct decompression | Moderate | |
| • | | |



Use of Exogenous Enzymes for Pain

| Study | Preparation | Response |
|-----------------|-------------|----------|
| lsaksson (1983) | uncoated | yes |
| Slaff (1984) | uncoated | yes |
| Halgreen (1986) | coated | no |
| Mossner (1992) | coated | no |
| Malesci (1995) | coated | no |





Steatorrhea

Stool with excessive fat



Sudan stain


Mechanisms


- Decreased concentration of lipase and colipase
- Duodenal pH
 - Inactivation of pancreatic lipase pH<4.5
 - Precipitation of bile salts



Pancreatic Cancer Risk

3-15 fold increase









Lowenfels, et al., N Engl J Med 1993; 328:1433

Pancreatic Insufficiency Without Pancreatitis

Non-pancreatic

- Mucosal disease
 - \downarrow CCK release
 - Enterokinase deficiency *
- Gastrinoma
- Bilroth II reconstruction

Pancreatic

- Cystic fibrosis *
- Pancreatic tumors
- Shwachman-Diamond syndrome *
- Childhood pancreatic atrophy *
- Johanson-Blizzard syndrome*
- Adult lipomatosis or atrophy
- Protein-calorie malnutrition





Diagnostic Criteria: I

Imaging

Diffuse pancreatic duct narrowing Diffuse pancreatic enlargement

Immunity Autoantibodies Elevated gammaglobulins or IgG4

Histology

Periductular lymphoblastic infiltrate Phlebitis

Fibrosis






Autoimmune Pancreatitis

Presentation

Symptoms

- Asymptomatic or mild pain
- Acute pancreatitis, rare
- Obstructive jaundice

ImagingIncidental pancreatic mass





Autoimmune Pancreatitis

Diagnostic Criteria: II

Other organ involvement

- Biliary
- Liver
- Kidney
- Lung

Response to steroids



Autoimmune Pancreatitis

Patient Characteristics


Gender

• Male > female

Age • Wide range (20-80 years), most > 50 years Comorbidity • Autoimmune diseases











Tsiotos, 2002 Lankisch PG, Pancreatology 2001; 1:3